Author(s):
Amol R. Kharat, Savita B. Nikam, Priya Mijgar
Email(s):
savitanikam10@gmail.com
DOI:
10.52711/0974-360X.2026.00041
Address:
Amol R. Kharat1, Savita B. Nikam2, Priya Mijgar3
1Associate Professor, Government College of Pharmacy, Amravati, Maharashtra, India.
2M. Pharmacy, Government College of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India.
3M. Pharmacy, Government College of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 1,
Year - 2026
ABSTRACT:
The present research aims to develop and evaluate chlorzoxazone-loaded transdermal patches for the effective management of muscle spasms. These patches serve as an alternative to conventional oral dosage forms, which are often linked to systemic adverse effects. Chlorzoxazone, a centrally acting skeletal muscle relaxant, is widely prescribed to alleviate muscle pain and stiffness. However, oral administration frequently results in gastrointestinal irritation and inconsistent plasma drug concentrations. Transdermal drug delivery systems offer a promising approach by enabling sustained drug release and reducing systemic toxicity. In this study, different polymer combinations were utilized to optimize drug release and enhance skin permeability. The patches were fabricated using the solvent evaporation method, with varying concentrations of chlorzoxazone, polymers, plasticizers, and penetration enhancers. The prepared patches were evaluated for their mechanical and physicochemical properties, including thickness, weight uniformity, drug content, and in vitro release profile. Results indicated uniformity in thickness, weight, and drug loading, ensuring dose consistency. In vitro diffusion studies demonstrated a sustained release of chlorzoxazone for up to 12 hours. Overall, the developed chlorzoxazone transdermal patches represent a potential substitute for oral therapy, providing prolonged drug delivery and improved patient compliance.
Cite this article:
Amol R. Kharat, Savita B. Nikam, Priya Mijgar. Formulation and Evaluation Chlorzoxazone Transdermal Patches. Research Journal of Pharmacy and Technology. 2026;19(1):289-5. doi: 10.52711/0974-360X.2026.00041
Cite(Electronic):
Amol R. Kharat, Savita B. Nikam, Priya Mijgar. Formulation and Evaluation Chlorzoxazone Transdermal Patches. Research Journal of Pharmacy and Technology. 2026;19(1):289-5. doi: 10.52711/0974-360X.2026.00041 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-1-41
REFERENCES:
1. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. British Journal of Pharmacology. 2015; 172(9): 2179-209. DOI: 10.1111/bph.13059
2. Gannu R, Vamshi Vishnu Y, Kishan V, Madhusudan Rao YJ. Development of nitrendipine transdermal patches: n vitro and ex vivo characterization. Current Drug Delivery. 2007; 1; 4(1): 69-76. DOI: 10.2174/156720107779314767
3. Riviere JE, Papich MG. Potential and problems of developing transdermal patches for veterinary applications. Advanced Drug Delivery Reviews. 2001; 50(3): 175-203. DOI: 10.1016/s0169-409x(01)00157-0.
4. Kusum Devi V, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Development and Industrial Pharmacy. 2003; 29(5): 495-503. Doi: 10.1081/ddc-120018638.
5. Parivesh S, Sumeet D, Abhishek D. Design, evaluation, parameters and marketed products of transdermal patches: A review. J Pharm Res. 2010; 3(2): 235-40.
6. Cilurzo F, Gennari CG, Minghetti P. Adhesive properties: a critical issue n transdermal patch development. Expert Opinion on Drug Delivery. 2012; 9(1): 33-45. DOI: 10.1517/17425247.2012.637107
7. Tanwar Y, Chauhan C, Sharma A. Development and evaluation of carvedilol transdermal patches. Acta Pharmaceutical. 2007; 57(2): 151-9. DOI: 10.2478/v10007-007-0012-x
8. Patel RP, Patel G, Patel H, Baria A. Formulation and evaluation of transdermal patch of aceclofenac. Research Journal of Pharmaceutical Dosage Forms and Technology. 2009; 1(2): 108-15.
9. Arora P, Mukherjee B. Design, development, physicochemical, and n vitro and n vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. Journal of Pharmaceutical Sciences. 2002; 91(9): 2076-89. DOI: 10.1002/jps.10200
10. Al Hanbali OA, Khan HM, Sarfraz M, Arafat M, Ijaz S, Hameed A. Transdermal patches: Design and current approaches to painless drug delivery. Acta Pharmaceutica. 2019; 69(2): 197-215. DOI: 10.2478/acph-2019-0016
11. Roxhed N, Samel B, Nordquist L, Griss P, Stemme G. Painless drug delivery through microneedle-based transdermal patches featuring active infusion. IEEE Transactions on Biomedical Engineering. 2008; 55(3): 1063-71. DOI: 10.1109/TBME.2007.906492
12. Small G, Dubois B. A review of compliance to treatment n Alzheimer's disease: potential benefits of a transdermal patch. Current Medical Research and Opinion. 2007; 23(11): 2705-13. DOI: 10.1185/030079907x233403
13. Dhiman S, Singh TG, Rehni AK. Transdermal patches: a recent approach to new drug delivery system. Int J Pharm Pharm Sci. 2011; 3(5): 26-34.
14. Singh A, Bali A. Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride. Journal of Analytical Science and Technology. 2016; 7: 1-3.
15. Prabhakara P, Koland M, Vijaynarayana K, Harish NM, Shankar G, Ahmed MG, Narayana C, Satyanarayana D. Preparation and evaluation of transdermal patches of papaverine hydrochloride. Int J Res Pharm Sci. 2010; 1(3): 259-66.
16. Saroha K, Yadav B, Sharma B. Transdermal patch: A discrete dosage form. Int J Curr Pharm Res. 2011; 3(3): 98-108.
17. Prajapati ST, Patel CG, Patel CN. Formulation and evaluation of transdermal patch of repaglinide. International Scholarly Research Notices. 2011; 2011(1): 651909. DOI: 10.5402/2011/651909
18. Mutalik S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations. Journal of Pharmaceutical Sciences. 2004; 93(6): 1577-94. DOI: 10.1002/jps.20058
19. Isaac M, Holvey C. Transdermal patches: the emerging mode of drug delivery system n psychiatry. Therapeutic Advances n Psychopharmacology. 2012; 2(6): 255-63. DOI: 10.1177/2045125312458311
20. Yilmaz EG, Ece E, Erdem Ö, Eş I, Inci F. A sustainable solution to skin diseases: ecofriendly transdermal patches. Pharmaceutics. 2023; 15(2): 579. DOI: 10.3390/pharmaceutics15020579
21. Kanikkannan N, Andega S, Burton S, Babu RJ, Singh M. Formulation and n vitro evaluation of transdermal patches of melatonin. Drug Development and Industrial Pharmacy. 2004; 30(2): 205-12. DOI: 10.1081/ddc-120028716
22. Prabhu P, Shah S, Gundad S. Formulation development and investigation of domperidone transdermal patches. International Journal of Pharmaceutical Investigation. 2011; 1(4): 240. DOI: 10.4103/2230-973X.93008
23. Alam MI, Alam N, Singh V, Alam MS, Ali MS, Anwar T, Safhi MM. Type, preparation and evaluation of transdermal patch: a review. World Journal of Pharmacy and Pharmaceutical Sciences. 2013 May 21;2(4):2199-233.
24. Ah YC, Choi JK, Choi YK, Ki HM, Bae JH. A novel transdermal patch incorporating meloxicam: n vitro and n vivo characterization. International Journal of Pharmaceutics. 2010; 385(1-2): 12-9. DOI: 10.1016/j.jpharm.2009.10.013
25. Ananda PW, Elim D, Zaman HS, Muslimin W, Tunggeng MG, Permana AD. Combination of transdermal patches and solid microneedles for improved transdermal delivery of primaquine. International Journal of Pharmaceutics. 2021; 609: 121204. DOI: 10.1016/j.jpharm.2021.121204
26. Beny Baby, Abin Abraham, S Jayaprakash. Design and Evaluation of Transdermal Patches of Propanolol Hydrochloride. Research J. Pharm. and Tech. 2009; 2(1): 195-200.
27. Amjad M, Ehtheshamuddin M, Chand S, Hanifa SM, Asia R, Kumar GS. Formulation and evaluation of transdermal patches of atenolol. Advance Research n Pharmaceuticals and Biological. 2011; 1(2): 12-23.
28. Wohlrab J, Kreft B, Tamke B. Skin tolerability of transdermal patches. Expert Opinion on Drug Delivery. 2011; 8(7): 939-48. DOI: 10.1517/17425247.2011.574689
29. Jayaprakash S, Mohamed Halith S, Firthouse PM, Nagarajan YM. Preparation and evaluation of celecoxib transdermal patches. Pakistan Journal of Pharmaceutical Sciences. 2010; 23(3).
30. Sheth NS, Mistry RB. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of eugenol. Journal of Applied Pharmaceutical Science. 2011 May 30(Issue):96-101.
31. Ren C, Fang L, Ling L, Wang Q, Liu S, Zhao L, He Z. Design and n vivo evaluation of an indapamide transdermal patch. International Journal of Pharmaceutics. 2009 Mar 31; 370(1-2): 129-35.
32. Dey BK, Kar PK, Nath LK. Formulation Design, Preparation and In vitro – In vivo Evaluation of Propranolol Hydrochloride Transdermal Patches using Hydrophilic and Hydrophobic Polymer complex. Research J. Pharm. and Tech. 2009; 2(1): 155-160
33. Hakraborty Prithviraj, Dey Biplab K., Bahadur Sanjib, Thakkar Suresh, Das Sudip. Design, Development, Physicochemical and In Vitro Evaluation of Transdermal Patches Containing Verapamil Hydrochloride n Ethyl Cellulose - Povidone Matrices. Research J. Pharm. and Tech. 2009; 2(1): 168-172.